The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
US rare diseases focused biotech Quince Therapeutics today announced the online publication of data in The Lancet Neurology from its Phase III ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem clinical trial evaluating the safety and efficacy of its lead asset, EryDex. 15 August 2024
The World Health Organization (WHO) has declared the ongoing surge of mpox cases in the Democratic Republic of the Congo (DRC) and other African countries a public health emergency of global concern. 15 August 2024
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review by the US Food and Drug Administration (FDA). 15 August 2024
Th US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare liver disease, said Gilead Sciences 15 August 2024
Japanese drugmaker Chugai Pharmaceutical has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD). 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
Texas-based Lexicon Pharmaceuticals has announced that, following a strategic review of the company’s commercial and pipeline programs, it will refocus resources across the portfolio and cut jobs. 14 August 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 1 October 2024